StreetAlpha.app
Home › Stocks › ARTV

Artiva Biotherapeutics, Inc. (ARTV)

Healthcare
$3.78
▼ −1.31%
LAST CLOSE · NOV 20

Artiva develops natural killer cell therapies for autoimmune diseases and cancers, based in San Diego, California. It last closed at $3.78 on Nov 20, down 1.31% on the day. The next earnings report for ARTV is expected around Tue, Mar 9, 2027, after the close. Over its last 8 reports the stock moved an average of 11.0% the session after earnings. Over the last 12 months ARTV insiders bought $109.1M of stock on the open market and sold $3.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is ARTV in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ARTV.

Key Stats

Fiscal 2025
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$83.9M
EPS (diluted)
−$3.43
Free cash flow
−$79.3M
Valuation
Market cap
$186.9M
49.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$61.2M
At Sep 30
Shareholder equity
$320.7M
Shares outstanding
49.4M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $33.5M$33.5MFY2023FY2024: $251K$251KFY2024FY2025: $0$0FY2025

From ARTV's SEC filings, latest 10-Q for the period ending Dec 31, 2025 (filed Nov 9).

Next report
Mar 9
Estimated date · After the close
Reported EPS
—
Not on file yet
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
How ARTV moved after its last 8 reports
Average move the session after a report ±11.0%
Oct 27, 2026Time not announced−30.7%
Aug 6, 2026After the close−2.7%
May 8, 2026Time not announced−13.0%
Mar 10, 2026After the close+17.3%
Nov 12, 2025Time not announced+10.9%
Aug 6, 2025After the close−8.0%
May 8, 2025Time not announced+3.8%
Mar 24, 2025After the close+2.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ARTVStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ARTV
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ARTV

Technical Analysis

ARTV · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 10% below its 20 day and 58% below its 50 day average. It is 112% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the Pivot S1 at $3.72, and the nearest resistance the Pivot at $3.83.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityLow, 6.9%/day
Key levels
$14.5352 week high+284.4%
$8.30100 day average+119.6%
$8.00200 day average+111.6%
$5.9750 day average+57.9%
$4.28Swing high (Nov 4)+13.2%
$4.1820 day average+10.6%
$3.88Pivot R1+2.6%
$3.83Pivot+1.3%
$3.78Last close
$3.72Pivot S1−1.6%
$2.9652 week low−21.7%
Indicators
RSI (14)22.21Oversold below 30Oversold
MACD-0.67Above its signal lineBullish
Stochastic8.2Near the bottom of its rangeOversold
ADX (14)60.5Strong downtrend
Williams %R-94.3Oversold below −80, overbought above −20Oversold
CCI (20)-109.4Oversold below −100, overbought above 100Oversold
Rate of change−8.9%Change over 10 sessionsBearish
ATR (14)$0.26Typical daily range, 6.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ARTV

What happened before

See how ARTV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for ARTVHow many large options trades hit ARTV, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ARTV Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲62 buying vs 21 selling
  • ▲Held by funds +1.1 pts
  • ▲Funds holding +26
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9872+36.1%
In funds' top 1023−33.3%
Held by funds83.3%82.3%+1.1 pts
New / increased32 / 3039 / 25−3.1%
Reduced / sold out15 / 62 / 7+133.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ARTV institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ARTV Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$109.1M10 buys · 2 insiders
Sold$3.5M27 sales · 6 insiders
16% of the selling was under pre-arranged trading plans.
Cluster buy: 2 insiders bought $94.8M between May 11 and Jun 10.
2025-12 sold $19K2026-05 bought $91.5M2026-05 sold $478K2026-06 bought $12.5M2026-07 bought $5.1M2026-08 sold $104K2026-09 sold $1.2M2026-10 sold $726K2026-11 sold $987KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Fred AslanCEOSale119,771$3.91$469K
Nov 17Subhashis BanerjeeChief Medical OfficerSale4,037$3.91$16K
Nov 17Jennifer BushCOO, CLO, Compliance OfficerSale19,217$3.91$75K
Nov 17Christopher HoranChief Tech Operations OfficerSale20,546$3.91$80K
Nov 17Gines Diego MirallesPresident & Head of R&DSale1,043$3.91$4K
Nov 2Fred AslanCEOSale62,178$4.18$260K
Every insider buy and sale for ARTV over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ARTV insider trades →

From SEC Form 4 filings by ARTV's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARTV is in one of them and how their past ARTV trades turned out.

ARTV in the AI portfolios
Loading…

ARTV News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ARTV in an article yet. Here's the latest on the wider market.

ARTV in the news

About Artiva Biotherapeutics

Artiva is a biotechnology company based in San Diego, California, that is developing cell therapies made from natural killer cells, a type of immune cell. Its lead product candidate, AlloNK, is made from donor cells, frozen and shipped ready for use, and is designed to work alongside antibody medicines to deplete B cells. The company is testing AlloNK in clinical trials for autoimmune diseases such as rheumatoid arthritis and Sjögren's disease, and it also has programs aimed at cancers. The intended patients are people with these conditions, and the product is not yet approved for sale.

Headquarters
San Diego, CA